Skip to content

Released Aug 1, 2023, before the open

10-Q filed Aug 9, 2023, 38 days after period end · 0000078003-23-000088

Q2 2023 · 10-Q
Revenue$13.01B−53.1% vs Q2 2022−29.6% vs Q1 2023
Net Income$2.33B−76.5% vs Q2 2022−58.0% vs Q1 2023
EPS Diluted$0.41−76.3% vs Q2 2022−57.7% vs Q1 2023
Operating Cash Flowderived-$1,208,000,000N/M
Free Cash Flowderived-$2,122,000,000N/M
Margins · derived
Net margin17.9%−17.8 pt vs Q2 2022

What the release said

The release

Same quarter

MetricQ2 2023Q2 2022Q2 2021Q2 2020
Revenue$13.01B$27.74B$18.90B$9.86B
Net Income$2.33B$9.91B$5.56B$3.49B
EPS Diluted$0.41$1.73$0.98$0.62

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR